Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis |
| |
| Authors: | Pepys M B Herbert J Hutchinson W L Tennent G A Lachmann H J Gallimore J R Lovat L B Bartfai T Alanine A Hertel C Hoffmann T Jakob-Roetne R Norcross R D Kemp J A Yamamura K Suzuki M Taylor G W Murray S Thompson D Purvis A Kolstoe S Wood S P Hawkins P N |
| |
| Affiliation: | Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine, Royal Free and University College Medical School, London NW3 2PF, UK. m.pepys@rfc.ucl.ac.uk |
| |
| Abstract: | The normal plasma protein serum amyloid P component (SAP) binds to fibrils in all types of amyloid deposits, and contributes to the pathogenesis of amyloidosis. In order to intervene in this process we have developed a drug, R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid, that is a competitive inhibitor of SAP binding to amyloid fibrils. This palindromic compound also crosslinks and dimerizes SAP molecules, leading to their very rapid clearance by the liver, and thus produces a marked depletion of circulating human SAP. This mechanism of drug action potently removes SAP from human amyloid deposits in the tissues and may provide a new therapeutic approach to both systemic amyloidosis and diseases associated with local amyloid, including Alzheimer's disease and type 2 diabetes. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
